Research programme: hepatitis C therapies - Ligand/Roche

Drug Profile

Research programme: hepatitis C therapies - Ligand/Roche

Alternative Names: HCV prodrugs - Ligand/Roche; HCV therapies - Ligand/Roche; MB 11362

Latest Information Update: 04 Feb 2010

Price : $50

At a glance

  • Originator Metabasis Therapeutics; Roche
  • Developer Ligand Pharmaceuticals; Roche
  • Class Nucleosides
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical Hepatitis C

Most Recent Events

  • 29 Jan 2010 Metabasis Therapeutics has been acquired by Ligand Pharmaceuticals
  • 09 Jun 2009 Preclinical development is ongoing
  • 08 Aug 2008 Preclinical trials in Hepatitis C in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top